On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes-Reference-Cited by-同舟云学术

On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes

Published:2017-07 Issue:4 Volume:13 Page:778-788
ISSN:1551-7411
Container-title:Research in Social and Administrative Pharmacy
language:en
Short-container-title:Research in Social and Administrative Pharmacy

Author:

Seetasith Arpamas,Holdford David,Shah Anal,Patterson Julie

Publisher

Elsevier BV

Subject

Pharmaceutical Science,Pharmacy

Reference43 articles.

1. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease;Hayat;Patient Prefer Adherence,2008

2. Food & Drug Administration. Epoetin Alfa Package Labeling. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5122lbl.pdf; Accessed 24.06.2011.

3. Food & Drug Administration. Darbepoetin Alfa Package Labeling. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103951s5139lbl.pdf; Accessed 24.06.2011.

4. Regulating off-label drug use — rethinking the role of the FDA;Stafford;N Engl J Med,2008

5. Off-label prescribing of erythropoiesis stimulating proteins in US hospitals;Patkar;Drug Inf J,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for de-implementation of low-value care—a scoping review;Implementation Science;2022-10-27

2. Off-Label Use of Antineoplastic Drugs to Treat Malignancies: Evidence From China Based on a Nationwide Medical Insurance Data Analysis;Frontiers in Pharmacology;2021-04-08

3. Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA 's risk evaluation and mitigation strategy lifecycle;Pharmacoepidemiology and Drug Safety;2021-02-22

4. Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database;BioDrugs;2021-01-13

5. Off-label use of tamoxifen in a Chinese tertiary care hospital;International Journal of Clinical Pharmacy;2019-01-25